

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-9. (Canceled)

10. (Currently Amended) An isolated, enriched or purified ALK-7 polypeptide comprising:

(a) the full length amino acid sequence set forth in SEQ ID NO: 2,

(b) an amino acid sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 2,

(c) the catalytic domain encoded by amino acid residues 193-485 of SEQ ID NO: 2, or

(d) the cytoplasmic domain encoded by amino acid residues 137-493 of SEQ ID NO: 2.

11-22. (Canceled)

23. (Previously Presented) The ALK-7 polypeptide of claim 10, having an amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: 2.

24. (Currently Amended) The ALK-7 polypeptide of claim 10 ~~12~~, comprising ~~one or more of the following segments of the catalytic domain encoded by amino acid residues 193-485~~ of SEQ ID NO: 2: ~~26-113 and 193-485~~.

25. (Canceled)

26. (Currently Amended) The polypeptide of claim 10 ~~12~~, further comprising a second polypeptide fused to said ALK-7 polypeptide.

27. (Previously Presented) The polypeptide of claim 26, wherein said second polypeptide is GST.

28. (New) The ALK-7 polypeptide of claim 10, comprising the full length amino acid sequence set forth in SEQ ID NO: 2.
29. (New) The ALK-7 polypeptide of claim 10, comprising the cytoplasmic domain encoded by amino acid residues 137-493 of SEQ ID NO: 2.